Morpheus8 for Acne Scars: What the Evidence Shows

Acne scarring is one of the most common reasons people go looking at this device, and it is the indication where the evidence is least comfortable. There is a real Morpheus8 dataset behind it, and parts of it are encouraging. There is also an independent pooled analysis of randomised trials that points the other way, and a regulatory position siding with the pooled analysis rather than the dataset. Any page telling you the question is settled has quietly decided which half of that to show you, so here is all of it.

The two pieces of evidence, side by side

Both are real published work, and they are not the same kind of thing.

What the sponsor-linked acne paper found

The data comes from a 2025 retrospective in the Aesthetic Surgery Journal comparing 356 acne patients across three modalities, with 139 in the radiofrequency microneedling arm, each having 3 sessions. Two separate things were measured, and separating them matters.

The first is relapse. Over three years it occurred in 7 of 29 patients treated with radiofrequency microneedling, or 24 percent, against 36 of 54 on isotretinoin at 67 percent and 12 of 16 after ablative laser at 75 percent. Satisfaction was rated 4.2 out of 5. Note the comparators: isotretinoin and ablative laser are used against acne itself rather than the scars it leaves. The denominators are also much smaller than the arms they came from, 29 patients out of 139.

The second is the scarring. In a subgroup of 49 patients with old acne scars, mean age 25.4, the ECCA scar score fell from 178 to 132, a change the authors report as a reduction of at least 50 percent. Satisfaction was 3.8 out of 5, and no adverse events were recorded.

One disclosure belongs in the same breath as those figures. The authors are InMode consultants, and the supplement the paper appears in was sponsored by InMode. They do state that they purchased their own devices, which is not the same as independence. The pattern runs through most of the branded literature, and it shapes how any Morpheus8 statistic should be read.

One arithmetic note, offered as a question rather than an accusation. A fall from 178 to 132 is 46 points, and the record sets that beside a reported reduction of at least 50 percent without reconciling the two. If a clinic quotes you the 50 percent, ask what it refers to.

What the independent pooled data found

This is the most important finding in this article, and it is almost never quoted on a clinic page.

A 2022 systematic review and meta-analysis, searching Embase, PubMed and the Cochrane library to 20 June 2021, pooled 12 randomised controlled trials covering 414 patients with acne scarring. Objective scar improvement was statistically significant for microneedling without radiofrequency, with a mean difference of 0.42. For fractional radiofrequency microneedling, the effect was not statistically significant. No secondary scarring or infection was reported, and the review was graded Level of Evidence III.

Pooled randomised evidence sits well above a single retrospective series in any hierarchy you care to name, and it found the effect for the cheaper, shallower, purely mechanical treatment and not for the version with radiofrequency added. That is independent evidence pointing away from the more expensive option, the opposite of what the price difference implies.

It cuts the other way too. A mean difference of 0.42 is modest: this is not a finding that plain microneedling transforms acne scarring, only that it produced a small detectable improvement where the radiofrequency version produced none the pooled data could tell apart from chance.

Not statistically significant describes what the available data could demonstrate. It is not proof that a treatment does nothing, and it can equally reflect fewer or smaller trials. But it is the honest state of the pooled randomised evidence, and nobody asking you to pay more for the deeper treatment gets to walk past it.

The regulator has taken the same side

Here the paperwork lines up with the meta-analysis rather than the retrospective.

Plain microneedling holds a specific FDA indication for exactly this problem. The SkinPen system is authorised for improving the appearance of facial acne scars in adults aged 22 and over, granted through the De Novo pathway with clinical study data submitted in support.

Morpheus8 holds nothing comparable. It has never been FDA approved. It is 510(k) cleared, a substantial-equivalence route establishing that a device resembles one already on the market, not that it works. The cleared wording covers dermatologic procedures where coagulation or contraction of soft tissue, or haemostasis, is needed. No Morpheus8 clearance names acne scars, wrinkles, skin tightening, cellulite, stretch marks or fat reduction. The soft tissue clearance it does hold was granted with clinical performance data recorded as not applicable, meaning bench data only.

They are not even filed as the same category of device: plain microneedling under 21 CFR 878.4430 as a microneedling device for aesthetic use, Morpheus8 under 21 CFR 878.4400 as an electrosurgical cutting and coagulation device. The wider comparison runs the same way on price and downtime.

Why the risks weigh differently here

Acne scarring gets treated on younger faces than almost anything else this device is used for. The mean age in that old scars subgroup was 25.4, which changes the arithmetic: someone of 25 has a great many years to live with an outcome they did not want.

On 15 October 2025 the FDA published a safety communication on the potential risks of certain uses of radiofrequency microneedling. It reports burns, scarring, fat loss, disfigurement, nerve damage and the need for surgical repair, and states plainly that radiofrequency microneedling is a medical procedure, not a cosmetic treatment. Scarring appearing on that list, in a treatment sold for scarring, is not a detail to hurry past.

Two further facts belong here. No sham-controlled randomised trial of Morpheus8 has been published, on any indication. And the only systematic review that explicitly excluded industry-funded studies rates the radiofrequency microneedling evidence base at Level of Evidence 5, the weakest tier there is.

Settings, skin type and the numbers to ask for

Credit where it is due, the acne paper publishes its parameters instead of hiding them. For Fitzpatrick types I to IV it reports the forehead treated at 1 mm at energy 25 in cycle mode, the cheeks at 2 to 3 mm at 30 to 45 in fixed mode, and the neck at 2 mm at 30 to 40 in cycle mode. For types V to VI, energies were reduced by roughly 20 percent.

Hold on to that last line, because acne scarring is not distributed evenly across skin tones and neither is the risk. The FDA clearance restricts energies above 62 mJ per pin to Fitzpatrick types I to IV. The manufacturer’s manual says types V and dark VI should be treated with caution, capped at energy level 20, and the review literature advises avoiding the 0.5 mm resurfacing tip altogether in V and VI. A clinic telling you the treatment needs no adjustment for your skin tone is contradicting the manufacturer, not reassuring you.

Where the deeper device could still have a case

None of this means a clinic offering it for scarring is acting in bad faith.

The argument is depth, and essentially only depth. Plain microneedling works in the epidermis and the upper dermis: the SkinPen maximum setting is 2.5 mm, and its safety and effectiveness were never evaluated above 1.5 mm. The Morpheus8 manual offers 1 to 7 mm, with roughly a further millimetre of thermal effect beyond where the needle stops, and above about 4 mm it is heating subcutaneous fat rather than skin. Where scarring is bound down deep, or where the real complaint is contour rather than surface texture, a treatment confined to the upper dermis has less to reach. That is the reasoning that puts this device on jowls, the jawline and the neck, where it has a better claim.

What is missing is any trial testing that reasoning on scars. And the one independent randomised comparison against another modality went the other way: on the neck, a 1550 nm non-ablative fractional laser outperformed radiofrequency microneedling on wrinkle score, 42.1 percent against 8.6 percent. Different indication and different tissue, but a reminder that reaching deeper settles nothing on its own.

What to ask before you pay for it

If you still have active acne, that needs a diagnosis rather than a device. See your GP or a dermatologist first and get the acne under control before anyone treats what it left behind. The same goes for scarring nobody medical has looked at. There is a hard timing rule too: the manufacturer lists isotretinoin within the previous 6 months as a contraindication, which rules out a great many people who have only just finished a course.

Past that, the useful questions are narrow. Which of my scar types do you expect this to help, and which will it not touch. What depth and what energy, on which part of my face, adjusted for my skin type. What evidence are you relying on, and who funded it. And why this rather than the treatment that holds the acne scar indication and costs a fraction as much.

Book a consultation with us and we will answer those in plain numbers, including the answer some people should hear: that something simpler would serve them better.